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Abstract 
We report the first case of nonarteritic anterior ischemic neuropathy (NAION) associated 
with double thrombophilia: protein S deficiency and prothrombin G20210A mutation. A 58-
year-old man is presented including the clinical and laboratory findings, cardiovascular 
profile and thrombophilia screening. The patient presented with 3/10 vision and an inferior 
altitudinal defect in the right eye. Funduscopic examination of the right eye revealed a 
hyperemic optic disk with blurred superior optic disk border and sectoral nerve fiber layer 
edema. Complete blood count, erythrocyte sedimentation rate and C-reactive protein were 
normal, suggesting a NAION. A workup of cardiovascular risk factors revealed 
hyperlipidemia, arterial hypertension and high-risk asymptomatic coronary artery disease. 
Due to the family history of deep vein thrombosis in the patient’s daughter, a thrombophilia 
screening was additionally performed. The results revealed a double thrombophilic defect, 
namely congenital protein S deficiency and heterozygosity for prothrombin G20210A 
mutation, which were also identified in the patient’s daughter. Anticoagulant warfarin 
therapy was initiated and the patient underwent a triple bypass surgery. At three-month 
follow-up, the right optic disk edema had resolved, leaving a pale superior optic nerve head. 
Visual acuity in the right eye had slightly improved to 4/10; however, the dense inferior 
altitudinal field defect had remained unchanged. The patient is currently treated with 
warfarin, atorvastatin, irbesartan and metoprolol. This case suggests that the first line of 
investigation in all patients with NAION involves assessment of cardiovascular risk factors. 
However, careful history taking will identify NAION patients who are eligible for additional 
thrombophilia screening: young patients without vasculopathic risk factors, bilateral or  
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recurrent NAION, idiopathic or recurrent venous thromboembolism (VTE), positive family 
history of VTE, and VTE in young age or in unusual sites (e.g. cerebral, hepatic, mesenteric, 
or renal vein). 
 
Introduction 
Nonarteritic anterior ischemic optic neuropathy (NAION) is a relatively frequent 
cause of irreversible vision loss in the middle-aged and elderly, with an estimated 
annual incidence of 2.3 per 100,000 [1]. The risk factors for NAION can be divided into 
two groups: systemic and ocular. The systemic factors include nocturnal hypotension, 
sleep apnea syndrome, arterial hypertension, diabetes mellitus, coronary artery 
disease, arteriosclerosis, hypercholesterolemia and prolonged surgical procedures such 
as spinal or cardiac bypass surgery [2–4]. A significant association of NAION with a 
number of ocular and optic nerve head conditions has also been reported. These 
include small and crowded optic disks, angle closure glaucoma or other causes of 
markedly raised intraocular pressure, optic disk drusen and cataract extraction [4, 5]. 
In addition, reports of thrombotic tendencies in some patients with NAION have raised 
the question of whether there is a causative link between thrombophilia and NAION [2, 
6, 7]. Here we present, to the best of our knowledge, the first case of NAION associated 
with combined protein S deficiency and heterozygosity for prothrombin G20210A 
mutation. 
Case Report 
A 58-year-old male patient presented with painless visual loss in his right eye upon awakening in 
the morning. His best-corrected visual acuity was 3/10 in the right eye and 10/10 in the left eye. A 
relative afferent pupillary defect was present in the right eye. Funduscopic examination of the right 
eye revealed a hyperemic optic disk with blurred superior optic disk border, sectoral nerve fiber layer 
edema, few flame-shaped peripapillary hemorrhages and solitary cotton-wool exudates. Examination 
of the fellow eye showed a small left optic disk with a cup-disk ratio of 0.2 and slight blurring of the 
nasal margin, indicating a probable contributory mechanical effect in the pathogenesis of the disease. 
Visual field testing demonstrated an inferior altitudinal defect in the right eye. Complete blood count, 
erythrocyte sedimentation rate and C-reactive protein were normal; therefore, the diagnoses of giant 
cell arteritis or other arteritic optic neuropathies were considered unlikely. The clinical and 
laboratory findings were compatible with NAION and a complete workup of potential cardiovascular 
risk factors was ordered. It revealed hyperlipidemia, arterial hypertension and high-risk coronary 
artery disease. Due to the family history of two episodes of deep vein thrombosis in the patient’s 
daughter (before and during pregnancy), a thrombophilia screening was additionally performed. 
Laboratory testing included protein C, protein S, antithrombin III, lupus anticoagulant, homocysteine 
level, anticardiolipin antibodies, activated protein C resistance and prothrombin G20210A mutation. 
The results revealed a double thrombophilic defect, namely congenital protein S deficiency and 
heterozygosity for prothrombin G20210A mutation, which were also identified in the patient’s 
daughter. Anticoagulant therapy with warfarin was initiated and the patient also underwent a triple 
bypass surgery. Follow-up visits were performed at 1 week, 2 weeks and at 1, 3, and 6 months. The 
patient is still under observation. At three-month follow-up, the right optic disk edema had resolved, 
leaving a pale superior optic nerve head (atrophy). Visual acuity in the right eye had slightly improved 
to 4/10; however, the dense inferior altitudinal field defect had remained unchanged. Re-evaluation 
at six months revealed no significant changes in visual acuity, funduscopic findings and visual field. 
The patient is currently treated with warfarin (target INR 2.5–3.0), atorvastatin (20 mg/day), 
irbesartan (150 mg/day) and metoprolol (25 mg twice a day).  
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Discussion 
The contribution of thrombophilic disorders to the pathogenesis of NAION is still 
under debate. Several observations have suggested that thrombophilic disorders, such 
as elevated homocysteine, lipoprotein(a) and high frequency of Leiden mutation, may 
be pathogenetically relevant in the development of NAION by increasing the risk for 
venous thromboembolism (VTE) [2, 6, 7]. On the other hand, recent studies did not 
demonstrate an association between NAION and a wide range of thrombophilic risk 
factors [3]. The principal clinical manifestation of thrombophilia is venous 
thromboembolism. However, NAION is primarily not a thromboembolic disorder but an 
arterial ischemic disorder of the optic nerve head [3, 8]. Its pathogenesis has been 
attributed to optic nerve head hypoperfusion, which is mostly due to nocturnal 
hypotension [5, 8]. An acute blood flow reduction in the prelaminar portion of the optic 
disk is generally accepted as the underlying mechanism for the development of NAION 
[5]. 
Six-month follow-up of the present patient revealed a slight improvement in visual 
acuity (from 3/10 to 4/10), which is in consistence with previous reports. In the review 
by Hayreh and Zimmerman [9] looking at the natural history of visual outcome in 
NAION, 41% of patients seen within two weeks of symptom onset and with initial 
visual acuity of 20/70 or worse showed improvement at 6 months. According to the 
same study, a significant change in visual function after 6 months is unlikely [9]. 
Therefore, although the patient is still under observation, a further change in his visual 
acuity or visual field is not expected unless a recurrence of NAION occurs. However, 
reported episodes of recurrence in the same eye are uncommon and range from 3% to 
6.4% [10, 11]. The only significant association for recurrence of NAION was with 
nocturnal arterial hypotension, while thrombophilia was not associated with 
recurrence of NAION [3, 10]. Although it is uncommon for NAION to recur in the same 
eye, it may involve the fellow eye in 14.7% of patients after a median follow-up of 5 
years [12]. A history of diabetes has been associated with increased risk of NAION in 
the fellow eye [13]. In a study by Salomon et al. [3], none of the parameters tested (i.e., 
gender, age at onset of first NAION, ischemic heart disease, hypercholesterolemia, 
diabetes, arrhythmia, hypertension, history of stroke, current smoking, crowded disk, 
and prothrombotic factors) proved to be significant predictors of second eye 
involvement. According to these findings, the risk of second eye involvement is not 
increased in the present patient. However, a regular follow-up is suggested, because 
NAION is a multifactorial disease and other risk factors so far unknown may also play a 
role. 
In conclusion, although we report the first case of NAION associated with a double 
thrombophilic defect (protein S deficiency and prothrombin G20210A mutation), the 
inference that NAION was invoked by the thrombophilia is difficult to reconcile with 
the cardiovascular risk profile and the crowded disks also coexistent in our patient. 
Hence we suggest that the first line of investigation in all patients with NAION involves 
assessment of cardiovascular risk factors, in order to detect and treat even life-
threatening conditions, such as coronary artery disease, whenever possible. However, it 
cannot be excluded that thrombogenic tendency may act as a trigger in susceptible 
individuals [14]. Therefore careful history taking is important, in order to identify 
NAION patients with thrombophilic defects. Thrombophilia screening is justifiable in  
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selected NAION cases: young (less than 45 years of age) patients without vasculopathic 
risk factors, bilateral simultaneous NAION or recurrent NAION in the same eye, 
idiopathic or recurrent VTE, positive family history of VTE, and VTE in young age or in 
unusual sites (e.g. cerebral, hepatic, mesenteric, or renal vein) [15, 16]. 
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